As secondary outcomes, we will observe changes in blood-based biomarkers levels, including Aβ protein, tau protein, HMGB, SERF 1A, and cholesterol derivatives, which are proposed to be associated with AD pathology [28]. Here, MAPT is linked to Alzheimer disease.